-
Electronic (PDF)
-
Site License
-
Enterprisewide
Reperfusion Injury - Pipeline Review, H1 2012
Global Markets Direct, June 2012, Pages: 101
Reperfusion Injury – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Reperfusion Injury - Pipeline Review, H1 2012', provides an overview of the Reperfusion Injury therapeutic pipeline. This report provides information on the therapeutic development for Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reperfusion Injury. 'Reperfusion Injury - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Reperfusion Injury.
- A review of the Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Reperfusion Injury pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Reperfusion Injury.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Reperfusion Injury pipeline depth and focus of Reperfusion Injury therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Reperfusion Injury Therapeutic Products under Development, Key Players in Reperfusion Injury Therapeutics, Reperfusion Injury Pipeline Overview, Reperfusion Injury Pipeline, Reperfusion Injury Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reperfusion Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Reperfusion Injury
Reperfusion Injury Therapeutics under Development by Companies
Reperfusion Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Reperfusion Injury Therapeutics – Products under Development by Companies
Reperfusion Injury Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Reperfusion Injury Therapeutics Development
Pharming Group N.V.
BioLineRx, Ltd.
Cephalon, Inc.
Cytomedix, Inc.
Proteo, Inc.
NeuroVive Pharmaceutical AB
SCYNEXIS, Inc.
Trophos SA
Alligator Bioscience AB
Opsona Therapeutics Ltd.
Omeros Corporation
APEPTICO Forschung und Entwicklung GmbH
Mt Cook Pharma. Inc.
Ischemix
Reperfusion Injury – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Elafin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRO40303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADC-1004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMS721 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMX-2043 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inhaled Nitric Oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allopurinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosiglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sevorein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendavia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propofol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CicloMulsion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Evasin-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ruconest - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophilin D Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS605240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDP 09 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reperfusion Injury Therapeutics – Drug Profile Updates
Reperfusion Injury Therapeutics – Discontinued Products
Reperfusion Injury Therapeutics - Dormant Products
Reperfusion Injury – Product Development Milestones
Featured News & Press Releases
Jun 15, 2012: Pharming Provides Updates On Phase III Study Of RUCONEST
Apr 09, 2012: Stealth Peptides Reports Results From Phase I Clinical Drug Interaction Studies With Bendavia
Dec 12, 2011: Pharming Receives US Patent On C1 Inhibitor Use In Ischemia Reperfusion Injury Indication
Dec 12, 2011: Pharming Receives US Patent On C1 Inhibitor Use In Ischemia Reperfusion Injury Indications
Nov 28, 2011: Stealth Peptides Announces Presentation Of Data On Bendavia At 2011 American Heart Association Annual Meeting
Nov 15, 2011: Researchers Present Promising Bendavia Findings At Annual American Society Of Nephrology Meeting
Dec 14, 2010: New MitoCare Consortium Receives €6m From EU To Study TRO40303
Sep 02, 2008: Fibrex Medical Reports Positive Phase II Results for FX06
Nov 30, 2007: Fibrex Medical Completes Enrolment of Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction
Oct 09, 2006: Fibrex Medical Initiates Phase II Trial of Treatment for Reperfusion Injury in Myocardial Infarction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Reperfusion Injury, H1 2012
Products under Development for Reperfusion Injury – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Pharming Group N.V., H1 2012
BioLineRx, Ltd., H1 2012
Cephalon, Inc., H1 2012
Cytomedix, Inc., H1 2012
Proteo, Inc., H1 2012
NeuroVive Pharmaceutical AB, H1 2012
SCYNEXIS, Inc., H1 2012
Trophos SA, H1 2012
Alligator Bioscience AB, H1 2012
Opsona Therapeutics Ltd., H1 2012
Omeros Corporation, H1 2012
APEPTICO Forschung und Entwicklung GmbH, H1 2012
Mt Cook Pharma. Inc., H1 2012
Ischemix, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Reperfusion Injury Therapeutics – Drug Profile Updates
Reperfusion Injury Therapeutics – Discontinued Products
Reperfusion Injury Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Reperfusion Injury, H1 2012
Products under Development for Reperfusion Injury – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
